HDFC Pharma and Healthcare Fund Direct Growth

HDFC Pharma and Healthcare Fund Direct Growth

NAV as on 28-03-2025

₹ 16.21

Inception Returns

38.9%

/yr

Historical NAV & Returns

Absolute

zero opening, trading, fund transfer fee
11562 people have invested ₹ 5.2Cr in HDFC Pharma and Healthcare Fund Direct Growth in the last three months

About HDFC Pharma and Healthcare Fund Direct Growth

HDFC Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 4 October, 2023. The fund is managed by . The fund could potentially beat inflation in the long-run.

Key Parameters

  1. HDFC Pharma and Healthcare Fund Direct Growth has ₹1469 Cr worth of assets under management (AUM) as on Feb 2025 and is less than category average.
  2. The fund has an expense ratio 0.9.

Returns

HDFC Pharma and Healthcare Fund Direct Growth has given a CAGR return of 38.90% since inception. Over the last 1 year the fund has given a CAGR return of 31.15%.

Holdings

HDFC Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Health, Corporate, Cash Equivalent, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Cipla Ltd, Lupin Ltd, Max Healthcare Institute Ltd Ordinary Shares

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 20%
For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefit
Dividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.

Investment objective of HDFC Pharma and Healthcare Fund Direct Growth

To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 100.00 and for SIP is INR 100.00. HDFC Pharma and Healthcare Fund Direct Growth has no lock in period.

HDFC Pharma and Healthcare Fund Direct Growth Overview

Expense ratio0.94%
Benchmark
S&P BSE Healthcare PR
AUM₹1469 Cr
Inception Date4 October, 2023
Min Lumpsum/SIP₹100/₹100
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
28.39%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

INDmoney Rank for HDFC Pharma and Healthcare Fund Direct Growth

Powered by IND quant engine
IND ranking is not available for this fund.
img
Among most bought funds within the category
img
No bad points found for this fund.

Trailing Returns

as on (28-Mar-25)

Period
HDFC Pharma and Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
9.4%
7.3%
7.5%
3M
-4.9%
-4.9%
-7.6%
6M
-0.7%
-12.9%
-7.9%
1Y
31.2%
5.4%
16.4%

Fund Distribution

as on (28-Feb-25)

  • Equity 97.5%

  • Debt & Cash 1%

Large cap
35%

Small cap
34.5%

Mid cap
26.5%

Sector Allocation

Feb'25

Jan'25

Dec'24

Health
98%
Basic Materials
2%
All changes are between Dec'24 and Feb'25
Dec'24
Fund Returns
3.49%
Nifty 500
-2.02%
Parameters
Feb'25
Jan'25
Dec'24
AUM
₹ 1.5K Cr
₹ 1.6K Cr
₹ 1.5K Cr
  • AUM of the fund stands at 1.5K Cr as of Feb'25
  • AUM decreased by 108.4 Cr between Feb'25 and Jan'25
Top Stocks bought last month
Suven Pharmaceuticals Ltd's allocation increased from 0.37% to 1.8%
Suven Pharmaceuticals Ltd's allocation increased from 0.37% to 1.8%
Alkem Laboratories Ltd's allocation increased from 2.06% to 2.65%
Alkem Laboratories Ltd's allocation increased from 2.06% to 2.65%
Divi's Laboratories Ltd's allocation increased from 8.5% to 8.91%
Divi's Laboratories Ltd's allocation increased from 8.5% to 8.91%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 12.29 % to 11.99 %
Sun Pharmaceuticals Industries Ltd's allocation decreased from 12.29 % to 11.99 %
Max Healthcare Institute Ltd Ordinary Shares's allocation decreased from 4.95 % to 4.87 %
Max Healthcare Institute Ltd Ordinary Shares's allocation decreased from 4.95 % to 4.87 %
Torrent Pharmaceuticals Ltd's allocation decreased from 3.83 % to 3.69 %
Torrent Pharmaceuticals Ltd's allocation decreased from 3.83 % to 3.69 %
Small Cap allocation has gone down from 34.6% to 34.5%
Small Cap allocation has gone down from 34.6% to 34.5%
Mid Cap allocation has gone up from 25.9% to 26.5%
Mid Cap allocation has gone up from 25.9% to 26.5%
Large Cap allocation has gone down from 35.3% to 35%
Large Cap allocation has gone down from 35.3% to 35%
Cash allocation has gone up from 0.9% to 0.9%
Cash allocation has gone up from 0.9% to 0.9%

Top 3 Sectors in February were Health, Corporate & Basic Materials

Feb'25
Health
98%
Corporate
58%
Basic Materials
2%
Jan'25
Health
98%
Corporate
53%
Basic Materials
2%
  • Gainers

  • Losers

Fund
Feb'25
Jan'25
Dec'24
No of Holdings
35
36
33
Top 5 Company Concentration
39.1%
38.8%
38.4%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (12%)
Sun Pharmaceuticals Industries Ltd (12.3%)
Sun Pharmaceuticals Industries Ltd (13.2%)
No of Sectors
3
3
3
Top 5 Sectors Concentration
158.2%
153%
128.9%
Sector having highest exposure
Health (98%)
Health (97.9%)
Health (98.1%)
Loading...
We are taking more time than usual
Fund House
HDFC Asset Management Co Ltd
Total Schemes
Total AUM
₹8.05L Cr
as on 28-Feb-2025
Address
HDFC Asset Management Company Limited,“HUL House”, 2nd Floor,,H.T. Parekh Marg,165-166, Backbay Reclamation,,Churchgate,
Phone
+912266316333
Website
cliser@hdfcfund.com

HDFC Pharma and Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 38.9% since inception which is more than its category average return of 17.1%
Fund Allocations

Fund Allocations

This fund has an allocation of 97.48% in Equity, 0% in Debt and 0.95% in Cash related instruments
AUM size ₹1469 Cr

AUM size ₹1469 Cr

This fund has AUM of ₹1469 Cr which is less than its category average of ₹ 1725 Cr
Expense Ratio 0.94%

Expense Ratio 0.94%

This fund has an expense ratio of 0.94% which is less than its category average expense ratio of 1.45%

More funds from HDFC

HDFC Infrastructure Fund -Direct Plan - Growth Option

HDFC Infrastructure Fund -Direct Plan - Growth Option

5Y CAGR

▲ 37.87

HDFC Mid-Cap Opportunities Fund -Direct Plan - Growth Option

HDFC Mid-Cap Opportunities Fund -Direct Plan - Growth Option

5Y CAGR

▲ 35.70

HDFC Focused 30 Fund -Direct Plan - Growth Option

HDFC Focused 30 Fund -Direct Plan - Growth Option

5Y CAGR

▲ 34.32

HDFC Flexi Cap Fund -Direct Plan - Growth Option

HDFC Flexi Cap Fund -Direct Plan - Growth Option

5Y CAGR

▲ 33.37

HDFC ELSS TaxSaver -Direct Plan - Growth Option

HDFC ELSS TaxSaver -Direct Plan - Growth Option

5Y CAGR

▲ 30.88

Frequently Asked Questions for HDFC Pharma and Healthcare Fund Direct Growth

The current NAV of HDFC Pharma and Healthcare Fund Direct Growth is ₹16.21 as on 28-Mar-2025.
Existing (Absolute + CAGR) as on 28-Mar-2025.
HDFC Pharma and Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
9.38%
9.38%
6 Month Returns
-0.74%
-0.74%
1 Year Returns
31.15%
31.15%
3 Years Returns
0%
0%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.94% as on March 2025
₹1469 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(11.99%), Divi's Laboratories Ltd(8.91%), Cipla Ltd(7.8%), Lupin Ltd(5.57%), Max Healthcare Institute Ltd Ordinary Shares(4.87%) as on March 2025
The alpha ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
8.54
-
-
As on March 2025
The alpha for HDFC Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
1
-
-
As on March 2025
The Beta for HDFC Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
0.66
-
-
As on March 2025
The sharpe ratio for HDFC Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the HDFC Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
HDFC Pharma and Healthcare Fund Direct Growth
18.97
-
-
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
The Exit load of HDFC Pharma and Healthcare Fund Direct Growth is 1%